Equasens has gained 6%, boosted by positive comments from Stifel, which has raised its recommendation from 'hold' to 'buy', with a price target raised from €66 to €83 for the healthcare software company.

At the dawn of a change in momentum, with growth set to accelerate in the second half of 2024, we believe there is a great opportunity to invest in a low-risk, high-quality company over the long term", the broker believes.

Copyright (c) 2024 CercleFinance.com. All rights reserved.